Paeds Vivas · growth-development-and-behaviour
Attention-deficit hyperactivity disorder — viva
Branching viva on ADHD diagnosis, mimics, multimodal treatment and monitoring.
On this page & tools
Target exams
Stem
Examiner-led viva on paediatric ADHD. [1]
Examiner: How do you open this “medication today” visit? [1]
Strong answer: I greet the child first, set a joint agenda, and reframe the request as a full multi-setting assessment: developmental history, function, mimics, comorbidity, school information and shared decision-making — not a same-day label from one complaint. [1]
Examiner: What age-of-onset number do you use? [1]
Strong answer: Onset of symptoms before age 12 in DSM-5-TR style criteria — not the old DSM-IV before-7 rule. [1]
Examiner: Sleep is 8 hours with screens. Why does that matter? [20]
Strong answer: School-age children often need roughly 9–12 hours’ sleep opportunity per AASM consensus. Short sleep is a reversible driver of ADHD-like behaviour and must be addressed before or alongside diagnostic labelling. [20]
Examiner: Diagnosis is confirmed moderate-severe combined ADHD. First-line plan? [1]
Strong answer: Psychoeducation, parent behavioural strategies and classroom supports plus carefully monitored stimulant medication for moderate-severe impairment, with growth, BP, HR, appetite, sleep, mood/tics and diversion review. [1] [3] [15]
Examiner: What did MTA show at 14 months? [4]
Strong answer: Carefully managed medication management and combined medication-plus-behavioural treatment were superior to behavioural treatment alone and community care for core ADHD symptoms. [4]
Examiner: Parent fears stimulants cause later drug abuse. Your reply? [17]
Strong answer: Meta-analytic evidence does not support stimulant therapy causing later substance abuse; untreated ADHD raises substance-use risk, and diversion is managed with long-acting formulations and monitoring. [17]
Examiner: Why might you choose atomoxetine? [13]
Strong answer: Stimulant intolerance, contraindication, high diversion risk, or preference for non-controlled continuous coverage; counsel that benefit builds over weeks toward roughly 1.2 mg/kg/day frameworks. [13]
Examiner: Adolescent driving risk? [27]
Strong answer: Untreated ADHD associates with higher relative traffic accident risk; counsel distraction, impulsivity, sleep, substances and medication timing, and document advice. [27]
References
- [1]Wolraich ML Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics, 2019.PMID 31570648
- [3]Cortese S Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry, 2018.PMID 30097390
- [4]The MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of general psychiatry, 1999.PMID 10591283
- [13]Michelson D Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. The American journal of psychiatry, 2002.PMID 12411225
- [15]Cooper WO ADHD drugs and serious cardiovascular events in children and young adults. The New England journal of medicine, 2011.PMID 22043968
- [17]Wilens TE Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 2003.PMID 12509574
- [20]Paruthi S Recommended Amount of Sleep for Pediatric Populations: A Consensus Statement of the American Academy of Sleep Medicine. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2016.PMID 27250809
- [27]Vaa T ADHD and relative risk of accidents in road traffic: a meta-analysis. Accident; analysis and prevention, 2014.PMID 24238842